Antibody drug cuts moderate Alzheimer’s decline, Swiss biotech cautions over results
https://healthell.blogspot.com/2021/08/antibody-drug-cuts-moderate-alzheimers.html
Antibody drug cuts moderate Alzheimer’s decline, Swiss biotech cautions over results
A Phase 2 trial involving an investigational monoclonal antibody drug, semorinemab, targeting the tau protein, reduced cognitive decline among adults with mild-to-moderate Alzheimer’s disease by about 44%, Swiss biotech AC Immune announced Tuesday.
